IIH EVOLVE Study Flyer - August 2022

Thank you for your interest in the Invex Therapeutics IIH EVOLVE Phase III Clinical Study.  To contact us please see our advice below:


This email address should be used by healthcare professionals either with an interest in or already working on Invex’s phase III IIH-EVOLVE clinical study.   Please note that all information on ongoing clinical trials including eligibility criteria and contact information are posted on the https://clinicaltrials.gov/ website under ClinicalTrials.gov Identifier: NCT05347147.

For IIH patient enquiries:

Please do not send us any information regarding your condition.

Should you want to see if you could be eligible for our IIH-EVOLVE study you can find more information and contact suggestions at https://clinicaltrials.gov/ct2/show/NCT05347147

Alternatively, you could contact your healthcare provider or find more information regarding your condition from patient organisations in your country of residence, for example:

For the UK – https://www.iih.org.uk/
For Australia – https://headacheaustralia.org.au or http://www.ihaustralia.org.au

For General Corporate or Investor enquiries:


This email address is for all queries regarding Corporate or Investor matters only.